Oct 12 (Reuters) – Bristol-Myers Squibb Company: * BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE INTERIM ANALYSIS OF PHASE 3 ACTION-1 FOR RYZ101, RAYZEBIO’S RADIOPHARMACEUTICAL
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
(Adds that the shareholding is through put options, Burberry no comment in paragraphs 3-4) LONDON,…
VIDEO SHOWS: HIGHLIGHTS OF THE ATP 1000 SHANGHAI MASTERS - ACTION FROM ROUND OF 32…
Founder & Managing Director, AM Realty Solutions | Real Estate Entrepreneur | Investor Advisor |…
By Tatiana Bautzer and Nupur Anand NEW YORK, Oct 12 (Reuters) - Citigroup is seeking…
By Leo Marchandon and Gabriel Stargardter PARIS, Oct 12 (Reuters) - Cyberattackers hit French supermarket…
JOHANNESBURG, Oct 12 (Reuters) - Offshore investors bought a net 2.23 billion rand ($134.79 million)…